Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage

International Journal of Oncology

Volumn 30, Issue 5, 2007, Pages 1089-1097

  Kawamata, Hitoshi ^a   Omotehara, Fumie ^a   Nakashiro, Koh Ichi ^b   Uchida, Daisuke ^c   Shinagawa, Yasuhiro ^a   Tachibana, Masatsugu ^a   Imai, Yutaka ^a   Fujimori, Takahiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Apoptosis; Head and neck cancer; Oncogenic mutation; p21waf1; p53

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL LINE; CELL SURVIVAL; CHEMISTRY; DNA DAMAGE; GENETICS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA, COMPLEMENTARY; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; OPEN READING FRAMES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447342033     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.5.1089     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Harrison LB, Sessions RB and Hong WK: Head and neck cancer: a multidisciplinary approach. Lippincott-Raven Publishers, Philadelphia, 1999.
3. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989.
4. Ko JL and Prives C: p53: puzzle and paradigm. Gene Dev 10: 1054-1072, 1996.
5. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
6. Donehower LA and Bradley A: The tumor suppressor p53. Biochim Biophys Acta 1155: 181-205, 1993.
7. Sigal A and Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788-6793, 2000.
8. IARC TP53 Mutation Database. http://www.iarc.fr/p53/
9. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J and Epstein CB: The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a 'gain of function' phenotype. Ann NY Acad Sci 768: 111-128, 1995.
10. Simpson L and Parsons R: PTEN: life as a tumor suppressor. Exp Cell Res 264: 29-41, 2001.
11. Srivastava S, Wang S, Tong YA, Hao ZM and Chang EH: Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis. Cancer Res 53: 4425-4452, 1993.
12. Milner J: DNA damage, p53 and anticancer therapies. Nat Med 1: 879-880, 1995.
13. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, Tada M, Van Meir EG, et al: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967, 1995.
14. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S and Iggo R: Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5: 124-129, 1993.
15. Yanagawa T, Hayashi Y, Yoshida H, Yura Y, Nagamine S, Bando T and Sato M: An adenoid squamous carcinoma-forming cell line established from an oral keratinizing squamous cell carcinoma expressing carcinoembryonic antigen. Am J Pathol 124: 496-509, 1986.
16. Shirasuna K, Sato M and Miyazaki T: A neoplastic epithelial duct cell line established from an irradiated human salivary gland. Cancer 48: 745-752, 1981.
17. Sato M, Azuma M, Hayashi Y, Yoshida H, Yanagawa T and Yura Y: 5-Azacytidine induction of stable myoepithelial and acinar cells from a human salivary intercalated duct cell clone. Cancer Res 47: 4453-4459, 1987.
18. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H and Sato M: Possible contribution of active MMP2 to lymph node metastasis and secreted cathepsin L to bone invasion of newly established human oral squamous cell cancer cell lines. Int J Cancer 70: 120-127, 1997.
19. Shinagawa Y, Kawamata H, Omotehara F, Nakashiro K, Hoque MO, Furihata T, Horiuchi H, Imai Y, Fujimori T and Fujibayashi T: Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53. Int J Oncol 22: 383-389, 2003.
20. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM and Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480, 1993.
21. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J and Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145: 702-714, 1994.
22. Horiuchi H, Kawamata H, Omotehara F, Fujii S and Fujimori T: Negative immunohistochemical staining of p53 protein does not always reflect wild type p53 gene in cancer cells. J Gastroenterol 39: 801-803, 2004.
23. Lane DP: On the expression of the p53 protein in human cancer. Mol Biol Rep 19: 23-29, 1994.
24. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I and Bier H: Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63: 1188-1191, 2003.
25. Hoque MO, Kawamata H, Nakashiro K, Omotehara F, Hino S, Uchida D, Harada K, Begum NM, Yoshida H, Sato M and Fujimori T: Dysfunction of the p53 tumor suppressor pathway in head and neck cancer. Int J Oncol 21: 119-126, 2002.
26. Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ and Chumakov PM: Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 21: 4595-4600, 2002.
27. Lin J, Teresky AK and Levine AJ: Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of the function phenotypes of human p53 mutants. Oncogene 10: 2387-2390, 1995.
28. Chene P and Bechter E: p53 mutants without a functional tetramerisation domain are not oncogenic. J Mol Biol 286: 1269-1274, 1999.
29. Blandino G, Levine AJ and Oren M: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485, 1999. (Pubitemid 29060623)
30. Yoshida Y, Izumi H, Torigoe T, Ishiguchi H, Itoh H, Kang D and Kohno K: p53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res 63: 3729-3734, 2003. (Pubitemid 36793059)
31. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M and Blandino G: Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275: 29503-29512, 2000.